Treatment Modalities for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136(5), E359–E386 (2015).
   PubMed Web of Science ®Google Scholar
• Herbst RS , HeymachJV, LippmanSM. Lung cancer. N. Engl. J. Med.359(13), 1367–1380 (2008).
   PubMed Web of Science ®Google Scholar
• Reck M , PopatS, ReinmuthNet al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.25(Suppl. 3), iii27–iii39 (2014).
   PubMed Web of Science ®Google Scholar
• Goffin J , LacchettiC, EllisPM, UngYC, EvansWK. Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J. Thorac. Oncol.5(2), 260–274 (2010).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG , JännePA, LeeJCet al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Pao W , MillerV, ZakowskiMet al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101(36), 13306–13311 (2004).
   PubMed Web of Science ®Google Scholar
• Soda M , ChoiYL, EnomotoMet al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature448(7153), 561–566 (2007).
   PubMed Web of Science ®Google Scholar
• Ullrich A , SchlessingerJ. Signal transduction by receptors with tyrosine kinase activity. Cell61(2), 203–212 (1990).
   PubMed Web of Science ®Google Scholar
• Morris SW , KirsteinMN, ValentineMBet al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science263(5151), 1281–1284 (1994).
   PubMed Web of Science ®Google Scholar
• Koivunen JP , MermelC, ZejnullahuKet al. EML4–ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res.14(13), 4275–4283 (2008).
   PubMed Web of Science ®Google Scholar
• Shaw AT , YeapBY, Mino-KenudsonMet al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK. J. Clin. Oncol.27(26), 4247–4253 (2009).
   PubMed Web of Science ®Google Scholar
• Wong DW-S , LeungEL-H, SoKK-Tet al. The EML4–ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer115(8), 1723–1733 (2009).
   PubMed Web of Science ®Google Scholar
• Takahashi T , SonobeM, KobayashiMet al. Clinicopathologic features of non-small-cell lung cancer with EML4–ALK fusion gene. Ann. Surg. Oncol.17(3), 889–897 (2010).
   PubMed Web of Science ®Google Scholar
• Camidge DR , KonoSA, FlaccoAet al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res.16(22), 5581–5590 (2010).
   PubMed Web of Science ®Google Scholar
• Lee JK , ParkHS, KimD-Wet al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer118(14), 3579–3586 (2012).
   PubMed Web of Science ®Google Scholar
• Camidge DR , KonoSA, LuXet al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol.6(4), 774–780 (2011).
   PubMed Web of Science ®Google Scholar
• Shaw AT , VargheseAM, SolomonBJet al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann. Oncol.24(1), 59–66 (2013).
   PubMed Web of Science ®Google Scholar
• Kut V , PatelJD, ArgirisA. Pemetrexed: a novel antifolate agent enters clinical practice. Expert Rev. Anticancer Ther.4(4), 511–522 (2004).
   PubMedGoogle Scholar
• Kwak EL , BangY-J, CamidgeDRet al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Ou S-HI , KwakEL, Siwak-TappCet al. Activity of crizotinib (PF02341066), a dual mesenchymal–epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol.6(5), 942–946 (2011).
   PubMed Web of Science ®Google Scholar
• Bergethon K , ShawAT, OuS-HIet al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol.30(8), 863–870 (2012).
   PubMed Web of Science ®Google Scholar
• Camidge DR , BangY-J, KwakELet al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol.13(10), 1011–1019 (2012).
   PubMed Web of Science ®Google Scholar
• Shaw AT , KimD-W, NakagawaKet al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med.368(25), 2385–2394 (2013).
   PubMed Web of Science ®Google Scholar
• Kim D-W , AhnM-J, ShiYet al. Results of a global Phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol.30, Abstract 7533 (2012).
   Web of Science ®Google Scholar
• Gerber DE , MinnaJD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell18(6), 548–551 (2010).
   PubMed Web of Science ®Google Scholar
• Ou S-HI . Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Rev. Anticancer Ther.12(2), 151–162 (2012).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , MokT, KimD-Wet al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med.371(23), 2167–2177 (2014).
   PubMed Web of Science ®Google Scholar
• Costa DB , ShawAT, OuS-HIet al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J. Clin. Oncol.33(17), 1881–1888 (2015).
   PubMed Web of Science ®Google Scholar
• Shaw AT , KimD-W, MehraRet al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med.370(13), 1189–1197 (2014).
   PubMed Web of Science ®Google Scholar
• Felip E , KimD-W, MehraRet al. Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Ann. Oncol.25(Suppl. 4), iv426–iv470 (2014).
   Google Scholar
• Mok T , SpiegelD, FelipEet al. ASCEND-2: a single-arm, open-label, multicenter Phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J. Clin. Oncol.3, Abstract 8059 (2015).
   Google Scholar
• Felip E , OrlovS, ParkKet al. ASCEND-3: a single-arm, open-label, multicenter Phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J. Clin. Oncol.33, Abstract 8060 (2015).
   Web of Science ®Google Scholar
• Seto T , KiuraK, NishioMet al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, Phase 1–2 study. Lancet Oncol.14(7), 590–598 (2013).
   PubMed Web of Science ®Google Scholar
• Ignatius Ou S-H , AhnJS, De PetrisLet al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global Phase 2 study (NP28673). J. Clin. Oncol.33, Abstract 8008 (2015).
   Web of Science ®Google Scholar
• Shaw AT , WestH, SocinskiMAet al. Updated efficacy/safety data from the Phase 2 NP28761 study of alectinib in ALK+ NSCLC. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6–9September2015 ( Abstract 1261).
   Google Scholar
• Gettinger S , BazhenovaL, SalgiaRet al. Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: Phase 1/2 trial results. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6–9September2015 ( Abstract 2125).
   Google Scholar
• Bauer TM , SolomonBJ, BesseBet al. Clinical activity and safety of the ALK/ROS1 TK inhibitor PF-06463922 in advanced NSCLC. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6–9September2015 ( Abstract 295).
   Google Scholar
• Heuckmann JM , Balke-WantH, MalchersFet al. Differential protein stability and ALK inhibitor sensitivity of EML4–ALK fusion variants. Clin. Cancer Res.18(17), 4682–4690 (2012).
   PubMed Web of Science ®Google Scholar
• Shackelford RE , VoraM, MayhallK, CotelingamJ. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer5(1–2), 1–14 (2014).
   PubMedGoogle Scholar
• Choi YL , SodaM, YamashitaYet al. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med.363(18), 1734–1739 (2010).
   PubMed Web of Science ®Google Scholar
• Pao W , MillerVA, PolitiKAet al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med.2(3), e73 (2005).
   PubMed Web of Science ®Google Scholar
• Gorre ME , MohammedM, EllwoodKet al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science293(5531), 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Sasaki T , KoivunenJ, OginoAet al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res.71(18), 6051–6060 (2011).
   PubMed Web of Science ®Google Scholar
• Katayama R , ShawAT, KhanTMet al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med.4(120), 120ra17 (2012).
   PubMed Web of Science ®Google Scholar
• Doebele RC , PillingAB, AisnerDLet al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res.18(5), 1472–1482 (2012).
   PubMed Web of Science ®Google Scholar
• Ignatius Ou S-H , AzadaM, HsiangDJet al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J. Thorac. Oncol.9(4), 549–553 (2014).
   PubMed Web of Science ®Google Scholar
• Mossé YP , LimMS, VossSDet al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group Phase 1 Consortium study. Lancet Oncol.14(6), 472–480 (2013).
   PubMed Web of Science ®Google Scholar
• Bresler SC , WoodAC, HaglundEAet al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med.3(108), 108ra114 (2011).
   PubMed Web of Science ®Google Scholar
• Sasaki T , OkudaK, ZhengWet al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res.70(24), 10038–10043 (2010).
   PubMed Web of Science ®Google Scholar
• Katayama R , KhanTM, BenesCet al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4–ALK. Proc. Natl Acad. Sci. USA108(18), 7535–7540 (2011).
   PubMed Web of Science ®Google Scholar
• Ou S-HI , JännePA, BartlettCHet al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann. Oncol.25(2), 415–422 (2014).
   PubMed Web of Science ®Google Scholar
• Marsilje TH , PeiW, ChenBet al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in Phase 1 and Phase 2 clinical trials. J. Med. Chem.56(14), 5675–5690 (2013).
   PubMed Web of Science ®Google Scholar
• Friboulet L , LiN, KatayamaRet al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov.4(6), 662–673 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT01685060. https://clinicaltrials.gov/show/NCT01685060.
   Google Scholar
• Clinical Trials Database: NCT01685138. https://clinicaltrials.gov/show/NCT01685138.
   Google Scholar
• Clinical Trials Database: NCT01828099. https://clinicaltrials.gov/show/NCT01828099.
   Google Scholar
• Clinical Trials Database: NCT01828112. https://clinicaltrials.gov/show/NCT01828112.
   Google Scholar
• Kinoshita K , AsohK, FuruichiNet al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg. Med. Chem.20(3), 1271–1280 (2012).
   PubMed Web of Science ®Google Scholar
• Sakamoto H , TsukaguchiT, HiroshimaSet al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell.19(5), 679–690 (2011).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT01801111. https://clinicaltrials.gov/show/NCT01801111.
   Google Scholar
• Clinical Trials Database: NCT01871805. https://clinicaltrials.gov/show/NCT01871805.
   Google Scholar
• Gadgeel SM , GandhiL, RielyGJet al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a Phase 1/2 study. Lancet Oncol.15(10), 1119–1128 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02075840. https://clinicaltrials.gov/show/NCT02075840.
   Google Scholar
• Katayama R , FribouletL, KoikeSet al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res.20(22), 5686–5696 (2014).
   PubMed Web of Science ®Google Scholar
• Ou S-HI , KlempnerSJ, GreenboweJRet al. Identification of a novel HIP1–ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J. Thorac. Oncol.9(12), 1821–1825 (2014).
   PubMed Web of Science ®Google Scholar
• Toyokawa G , HiraiF, InamasuEet al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J. Thorac. Oncol.9(12), e86–e87 (2014).
   PubMed Web of Science ®Google Scholar
• Ceccon M , MologniL, GiudiciGet al. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM–ALK-positive anaplastic large cell lymphoma. Mol. Cancer Res.13(4), 775–783 (2015).
   PubMed Web of Science ®Google Scholar
• Kodama T , TsukaguchiT, YoshidaM, KondohO, SakamotoH. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett.351(2), 215–221 (2014).
   PubMed Web of Science ®Google Scholar
• Ou S-HI , MillikenJC, AzadaMC, MillerVA, AliSM, KlempnerSJ. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer91, 70–72 (2016).
   PubMed Web of Science ®Google Scholar
• Gouji T , TakashiS, MitsuhiroT, YukitoI. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?J. Thorac. Oncol.9(3), e27–e28 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang S , WangF, KeatsJet al. AP26113, a potent ALK inhibitor, overcomes mutations in EML4–ALK that confer resistance to PF-02341066. Cancer Res.70, LB–298 (2010).
   Google Scholar
• Squillace RM , AnjumR, MillerDet al. AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions. Cancer Res.73, Abstract 5655 (2013).
   Web of Science ®Google Scholar
• Clinical Trials Database: NCT01449461. https://clinicaltrials.gov/show/NCT01449461.
   Google Scholar
• Johnson TW , RichardsonPF, BaileySet al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo [4,3-h] [2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem.57(11), 4720–4744 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT01970865. https://clinicaltrials.gov/show/NCT01970865.
   Google Scholar
• Lovly CM , HeuckmannJM, de StanchinaEet al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res.71(14), 4920–4931 (2011).
   PubMed Web of Science ®Google Scholar
• Horn L , InfanteJ, BlumenscheinGet al. A Phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.32, Abstract 8030 (2014).
   Google Scholar
• Clinical Trials Database: NCT01625234. https://clinicaltrials.gov/show/NCT01625234.
   Google Scholar
• Sperduto PW , ChaoST, SneedPKet al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys.77(3), 655–661 (2010).
   PubMed Web of Science ®Google Scholar
• Gaspar L , ScottC, RotmanMet al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys.37(4), 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Sperduto PW , KasedN, RobergeDet al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol.30(4), 419–425 (2012).
   PubMed Web of Science ®Google Scholar
• Costa DB , KobayashiS, PandyaSSet al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol.29(15), e443–e445 (2011).
   PubMed Web of Science ®Google Scholar
• Kim YH , OzasaH, NagaiHet al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J. Thorac. Oncol.8(9), e85–e86 (2013).
   PubMed Web of Science ®Google Scholar
• Gandhi L , DrappatzJ, RamaiyaNH, OttersonGA. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J. Thorac. Oncol.8(1), e3–e5 (2013).
   PubMed Web of Science ®Google Scholar
• Takeda M , OkamotoI, NakagawaK. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J. Thorac. Oncol.8(5), 654–657 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang I , ZaorskyNG, PalmerJD, MehraR, LuB. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol.16(13), e510–e521 (2015).
   PubMed Web of Science ®Google Scholar
• Gottesman MM , AmbudkarSV. Overview: ABC transporters and human disease. J. Bioenerg. Biomembr.33(6), 453–458 (2001).
   PubMed Web of Science ®Google Scholar
• Tang SC , NguyenLN, SparidansRW, WagenaarE, BeijnenJH, SchinkelAH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer134(6), 1484–1494 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02336451. https://clinicaltrials.gov/show/NCT02336451.
   Google Scholar
• Kodama T , HasegawaM, TakanashiK, SakuraiY, KondohO, SakamotoH. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother. Pharmacol.74(5), 1023–1028 (2014).
   PubMed Web of Science ®Google Scholar
• Gadgeel S , ShawAT, GovindanRet al. Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK+ NSCLC. Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6–9 September 2015 ( Abstract 1219).
   Google Scholar
• Clinical Trials Database: NCT02094573. https://clinicaltrials.gov/show/NCT02094573.
   Google Scholar
• Mak KS , GainorJF, NiemierkoAet al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neurooncology17(2), 296–302 (2015).
   PubMed Web of Science ®Google Scholar
• Johung KL , YehN, DesaiNBet al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J. Clin. Oncol.34(2), 123–129 (2015).
   PubMed Web of Science ®Google Scholar
• Rubin P , GashDM, HansenJT, NelsonDF, WilliamsJP. Disruption of the blood–brain barrier as the primary effect of CNS irradiation. Radiother Oncol.31(1), 51–60 (1994).
   PubMed Web of Science ®Google Scholar
• Mima T , ToyonagaS, MoriK, TaniguchiT, OgawaY. Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation. Neurol. Res.21(2), 209–215 (1999).
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ , ScheierB, BurkeJMet al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol.7(12), 1807–1814 (2012).
   PubMed Web of Science ®Google Scholar
• Gan GN , WeickhardtAJ, ScheierBet al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int. J. Radiat. Oncol. Biol. Phys.88(4), 892–898 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02314364. https://clinicaltrials.gov/show/NCT02314364.
   Google Scholar
• Taipale M , JaroszDF, LindquistS. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol.11(7), 515–528 (2010).
   PubMed Web of Science ®Google Scholar
• Normant E , PaezG, WestKAet al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene30(22), 2581–2586 (2011).
   PubMed Web of Science ®Google Scholar
• Sequist LV , GettingerS, SenzerNNet al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol.28(33), 4953–4960 (2010).
   PubMed Web of Science ®Google Scholar
• Socinski MA , GoldmanJ, El-HariryIet al. A multicenter Phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Res.19(11), 3068–3077 (2013).
   PubMed Web of Science ®Google Scholar
• Sang J , AcquavivaJ, FriedlandJCet al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov.3(4), 430–443 (2013).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT01228435. https://clinicaltrials.gov/show/NCT01228435.
   Google Scholar
• Clinical Trials Database: NCT01562015. https://clinicaltrials.gov/show/NCT01562015.
   Google Scholar
• Clinical Trials Database: NCT01579994. https://clinicaltrials.gov/show/NCT01579994.
   Google Scholar
• Felip E , CarcerenyE, BarlesiFet al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol.23, ix152–ix174 (2012).
   Web of Science ®Google Scholar
• Clinical Trials Database: NCT01752400. https://clinicaltrials.gov/show/NCT01752400.
   Google Scholar
• Clinical Trials Database: NCT01772797. https://clinicaltrials.gov/show/NCT01772797.
   Google Scholar
• Woodhead AJ , AngoveH, CarrMGet al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem.53(16), 5956–5969 (2010).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT01712217. https://clinicaltrials.gov/show/NCT01712217.
   Google Scholar
• Brahmer JR , PardollDM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol. Res.1(2), 85–91 (2013).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT01285609. https://clinicaltrials.gov/show/NCT01285609.
   Google Scholar
• Lynch TJ , BondarenkoI, LuftAet al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol.30(17), 2046–2054 (2012).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02454933. https://clinicaltrials.gov/show/NCT02454933.
   Google Scholar
• Clinical Trials Database: NCT02143466. https://clinicaltrials.gov/show/NCT02143466.
   Google Scholar
• Clinical Trials Database: NCT02393625. https://clinicaltrials.gov/show/NCT02393625.
   Google Scholar
• Clinical Trials Database: NCT02511184. https://clinicaltrials.gov/show/NCT02511184.
   Google Scholar
• Clinical Trials Database: NCT01998126. https://clinicaltrials.gov/show/NCT01998126.
   Google Scholar
• Zou HY , FribouletL, KodackDPet al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell28(1), 70–81 (2015).
   PubMed Web of Science ®Google Scholar
• Chuang JC , NealJW, NiuX-M, WakeleeHA. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: current data and future prospects. Lung Cancer90(1), 1–7 (2015).
   PubMed Web of Science ®Google Scholar
• Gerber DE , OxnardGR, GovindanR. ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin. Pharmacol. Ther.97(5), 447–450 (2015).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02194738. https://clinicaltrials.gov/show/NCT02194738.
   Google Scholar
• Clinical Trials Database: NCT02193282. https://clinicaltrials.gov/show/NCT02193282.
   Google Scholar
• Clinical Trials Database: NCT02201992. https://clinicaltrials.gov/show/NCT02201992.
   Google Scholar
• Clinical Trials Database: NCT01822496. https://clinicaltrials.gov/show/NCT01822496.
   Google Scholar